{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:38:29Z","timestamp":1791189509729,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.jaad.2010.12.038","type":"journal-article","created":{"date-parts":[[2011,11,4]],"date-time":"2011-11-04T21:26:26Z","timestamp":1320441986000},"page":"486-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"title":["Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response"],"prefix":"10.1016","volume":"66","author":[{"given":"Robert H.","family":"Rosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Tyring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2010.12.038_bib1","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1158\/0008-5472.CAN-03-2837","article-title":"Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death","volume":"64","author":"Ogbourne","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2010.12.038_bib2","doi-asserted-by":"crossref","first-page":"8123","DOI":"10.4049\/jimmunol.177.11.8123","article-title":"Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate","volume":"177","author":"Challacombe","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2010.12.038_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2306\/scienceasia1513-1874.1983.09.081","article-title":"3-O-angeloylingenol, the toxic and skin irritant factor from latex of Euphorbia antiquorum L. (Euphorbiaceae) and from a derived Thai purgative and anthelmintic (vermifuge) drug","volume":"9","author":"Adolph","year":"1983","journal-title":"J Sci Soc Thailand"},{"key":"10.1016\/j.jaad.2010.12.038_bib4","first-page":"131","article-title":"Weeds of New South Wales","volume":"28","author":"Maiden","year":"1917","journal-title":"AG Gazette NSW"},{"key":"10.1016\/j.jaad.2010.12.038_bib5","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0031-9422(00)81076-6","article-title":"Biologically active diterpene esters from Euphorbia peplus","volume":"24","author":"Rizk","year":"1985","journal-title":"Phytochemistry"},{"key":"10.1016\/j.jaad.2010.12.038_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1440-0960.1988.tb00383.x","article-title":"Home treatment of skin cancer and solar keratoses","volume":"29","author":"Green","year":"1988","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2010.12.038_bib7","doi-asserted-by":"crossref","first-page":"928","DOI":"10.5694\/j.1326-5377.1976.tb141173.x","article-title":"Home treatment of basal cell carcinoma","volume":"1","author":"Weedon","year":"1976","journal-title":"Med J Aust"},{"key":"10.1016\/j.jaad.2010.12.038_bib8","unstructured":"Berman B. Discovery and development timeline of a novel treatment for actinic keratosis: PEP005 (ingenol mebutate) gel. Presented at: 2009 South Beach Symposium; February 12-16, 2009; Miami, FL."},{"key":"10.1016\/j.jaad.2010.12.038_bib9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/CAD.0b013e3280149ec5","article-title":"Proceedings of the First International Conference on PEP005","volume":"18","author":"Ogbourne","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jaad.2010.12.038_bib10","unstructured":"Anderson L, Welburn P. Maximum tolerated dose of PEP005 topical gel for the treatment of actinic keratosis. Poster P1503 presented at: American Academy of Dermatology 2007 Summer Meeting; August 1-5, 2007; New York, NY."},{"key":"10.1016\/j.jaad.2010.12.038_bib11","unstructured":"Freeman M, Oakley A, Siller G, Rosen R, Salmon P, Spelman L, et\u00a0al. Study to determine the optimal tolerated regimen of ingenol mebutate (PEP005) gel for actinic keratosis of the face or face and scalp. Poster P2010 presented at: Summer Academy 08, American Academy of Dermatology Meeting; July 30-August 3, 2008; Chicago, IL."},{"key":"10.1016\/j.jaad.2010.12.038_bib12","unstructured":"Welburn P, Dosik JS. Early phase clinical development of PEP005 topical gel for actinic keratoses. Poster P1504 presented at: 21st World Congress of Dermatology; October 1-5, 2007; Buenos Aires, Argentina."},{"key":"10.1016\/j.jaad.2010.12.038_bib13","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1158\/0008-5472.CAN-09-4303","article-title":"The skin cancer therapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets vasculature","volume":"70","author":"Li","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2010.12.038_bib14","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1358\/dof.2005.030.10.942816","article-title":"PEP-005","volume":"30","author":"Hampson","year":"2005","journal-title":"Drugs Future"},{"key":"10.1016\/j.jaad.2010.12.038_bib15","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jaad.2009.01.008","article-title":"Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis","volume":"60","author":"Anderson","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.12.038_bib16","unstructured":"Spencer JM, Rosen R. Safety and efficacy of PEP005 (ingenol mebutate) gel, 0.05%, 0.01%, and 0.015% for actinic keratosis on the head (face and scalp). Presented at: Summer Academy 2009, American Academy of Dermatology Meeting; July 31, 2009; Boston, MA."},{"key":"10.1016\/j.jaad.2010.12.038_bib17","unstructured":"Weiss JS, Anderson L. Study to determine the safety, tolerability, and efficacy of PEP005 (ingenol mebutate) gel for actinic keratosis of the dorsum of the hand. Poster 1901 presented at: Summer Academy 09, American Academy of Dermatology Meeting; July 31, 2009; Boston, MA."},{"key":"10.1016\/j.jaad.2010.12.038_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1440-0960.2008.00497.x","article-title":"PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicenter, phase IIa study","volume":"50","author":"Siller","year":"2009","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2010.12.038_bib19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.141.4.467","article-title":"Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials","volume":"141","author":"Korman","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.12.038_bib20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2007.01.047","article-title":"Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head","volume":"57","author":"Jorizzo","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.12.038_bib21","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.12.038_bib22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4103\/0378-6323.27749","article-title":"Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study","volume":"72","author":"Fariba","year":"2006","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2010.12.038_bib23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","article-title":"Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses","volume":"40","author":"Wolf","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2010.12.038_bib24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","article-title":"Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel","volume":"146","author":"Rivers","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.12.038_bib25","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0149-2918(02)80012-1","article-title":"Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis","volume":"24","author":"Loven","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaad.2010.12.038_bib26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archderm.140.7.813","article-title":"Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial","volume":"140","author":"Jorizzo","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.12.038_bib27","first-page":"144","article-title":"Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp","volume":"6","author":"Tanghetti","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2010.12.038_bib28","unstructured":"Swanson N. Multicenter, randomized, parallel-group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.05% in patients with actinic keratoses (AK) on non-head locations. Abstract P105 presented at: 68th Annual Meeting of the American Academy of Dermatology; March 6, 2010; Miami Beach, FL."},{"key":"10.1016\/j.jaad.2010.12.038_bib29","doi-asserted-by":"crossref","first-page":"27327","DOI":"10.1074\/jbc.M702557200","article-title":"Luminal chloride-dependent activation of endosome calcium channels: patch clamp study of enlarged endosomes","volume":"282","author":"Saito","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaad.2010.12.038_bib30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/156652408783769571","article-title":"Ca2+ signaling, mitochondria and cell death","volume":"8","author":"Giorgi","year":"2008","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.jaad.2010.12.038_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood.V97.2.339","article-title":"The intriguing role of polymorphonuclear neutrophils in antitumor reactions","volume":"97","author":"Di Carlo","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2010.12.038_bib32","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00262-008-0458-9","article-title":"The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner","volume":"57","author":"Hampson","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jaad.2010.12.038_bib33","first-page":"226","article-title":"Targeted therapy of cancer: new prospects for antibodies and immunoconjugates","volume":"56","author":"Sharkey","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jaad.2010.12.038_bib34","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.vaccine.2009.03.025","article-title":"Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies","volume":"27","author":"Le","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jaad.2010.12.038_bib35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature07750","article-title":"Identification of a dendritic cell receptor that couples sensing of necrosis to immunity","volume":"458","author":"Sancho","year":"2009","journal-title":"Nature"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962211000144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962211000144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:23:47Z","timestamp":1759271027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962211000144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0190962211000144"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2010.12.038","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2010.12.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}